City of Hope

City of Hope, a NCI-designated Comprehensive Cancer Center

Page Title

Skip Navigation

Global Navigation



Border Border
  
Click here to login to Secure Web Site   (authorized users only)  
  
Search results:  62  Clinical trial(s) found  (Page 1 of 3 )
Results per page: 25 50 100 All 1-25 Trials Jump to page:

The following studies are available for :
COH Protocol Number: 15041 ClinicalTrials.gov Number: NCT02401048

Principal Investigator: Alex Herrera, MD
Sponsor: Industrial

Title:  A Multi-Center Open-Label Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with MEDI4736, in Subjects with Relapsed or Refractory Lymphomas

COH Protocol Number: 15005 ClinicalTrials.gov Number: NCT00697632

Principal Investigator: Karen Reckamp, MD
Sponsor: Industrial

Title:  Open-Label, Dose-Escalation Trial to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Daily Oral MGCD265 Administered Without Interruption to Patients with Advanced Malignancies

COH Protocol Number: 14352 ClinicalTrials.gov Number: NCT01915498

Principal Investigator: Anthony Stein, MD
Sponsor: Industrial

Title:  A Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-221 in Subjects with Advanced Hematologic Malignancies with an IDH2 Mutation

COH Protocol Number: 14349 ClinicalTrials.gov Number: NCT02342782

Principal Investigator: Jasmine Zain, MD
Sponsor: Institutional

Title:  Phase I Study of Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Plus Standard BEAM Conditioning for Autologous Hematopoietic Cell Transplantion in Patients with Mature T-Cell Non-Hodgkin Lymphoma: the aTAC-BEAM Regimen

COH Protocol Number: 14332 ClinicalTrials.gov Number: NCT02261220

Principal Investigator: Warren Chow, MD
Sponsor: Industrial

Title:  A Phase 1 Study of MEDI4736 (Anti-PD-L1 Antibody) in Combination with Tremelimumab (Anti-CTLA-4 Antibody) in Subjects with Advanced Solid Tumors

COH Protocol Number: 14308 ClinicalTrials.gov Number: NCT02257567

Principal Investigator: Alex Herrera, MD
Sponsor: Industrial

Title:  A Phase IB/II Study Evaluating the Safety, Tolerability and Anti-Tumor Activity of Polatuzumab Vedotin (DCDS54501A)in Combination with Rituzimab (R) or Obinutuzumab (G) Plus Bendamustine (B) in Relpased or Refractory Follicular or Diffuse Large B-Cell Lymphoma

COH Protocol Number: 14301 ClinicalTrials.gov Number: NCT02270463

Principal Investigator: Anthony Stein, MD
Sponsor: Industrial

Title:  A Phase 1/2 Study of SL-401 as Consolidation Therapy for Adult Patients with Adverse Risk Acute Myeloid Leukemia in First CR, and/or Evidence of Minimal Residual Disease (MRD) in First CR

COH Protocol Number: 14299 ClinicalTrials.gov Number: NCT02301104

Principal Investigator: Marwan Fakih, MD
Sponsor: Industrial

Title:  A Phase 1, Open-Label Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TAS-102 in Patients with Advanced Solid Tumors and Varying Degrees of Hepatic Impairment

COH Protocol Number: 14297 ClinicalTrials.gov Number: NCT02206334

Principal Investigator: Savita Dandapani, MD
Sponsor: Cooperative Group

Title:  NRG Oncology NRG-BR001: A Phase 1 Study of Stereotactic Body Radiotherapy (SBRT) for the Treatment of Multiple Metastases

COH Protocol Number: 14294 ClinicalTrials.gov Number: NCT02326584

Principal Investigator: Anthony Stein, MD
Sponsor: Industrial

Title:  A Phase 1b Dose-Escalation Study of SGN-CD33A in Combination with Standard-of-Care for Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)

COH Protocol Number: 14285 ClinicalTrials.gov Number: NCT02301117

Principal Investigator: Marwan Fakih, MD
Sponsor: Industrial

Title:  A Phase 1, Open-Label Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TAS-102 in Patients with Advanced Solid Tumors and Varying Degrees of Renal Impairment

COH Protocol Number: 14265 ClinicalTrials.gov Number: NCT01625234

Principal Investigator: Karen Reckamp, MD
Sponsor: Industrial

Title:  Phase 1/2, First-in-Human, Dose-Escalation Study of X-396 in Patients With Advanced Solid Tumors and Expansion Phase in Patients With ALK-positive Non-Small Cell Lung Cancer

COH Protocol Number: 14262 ClinicalTrials.gov Number: NCT01004224

Principal Investigator: Sumanta Pal, MD
Sponsor: Industrial

Title:  A Phase I, Open-Label, Multi-Center, Dose Escalation Study of Oral BGJ398, a Pan FGF-R Kinase Inhibitor, in Adult Patients with Advanced Solid Malignancies

COH Protocol Number: 14240 ClinicalTrials.gov Number: NCT02348216

Principal Investigator: Tanya Siddiqi, MD
Sponsor: Industrial

Title:  A Phase 1-2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-C19 in Subjects with Refractory Aggressive Non-Hodgkin Lymphoma (NHL)

COH Protocol Number: 14231 ClinicalTrials.gov Number: NCT02220842

Principal Investigator: Leslie Popplewell, MD
Sponsor: Industrial

Title:  A Phase 1b Sudy of the Safety and Pharmacology of MPDL3280A Administered with Obinutuzamab in Patients with Relpased/Refractory Follicular Lymphoma and Diffuse Large B-Cell Lymphoma

COH Protocol Number: 14220 ClinicalTrials.gov Number: NCT02203773

Principal Investigator: Vinod Pullarkat, MD
Sponsor: Industrial

Title:  A Phase 1b Study of ABT-199 (GDC-0199) in Combination with Azacitidine or Decitabine in Treatment Naïve Subjects with Acute Myelogenous Leukemia Who Are >/= 65 Years of Age and Who Are Not Eligible for Standard Induction Therapy

COH Protocol Number: 14212 ClinicalTrials.gov Number: NCT01998971

Principal Investigator: Amrita Krishnan, MD
Sponsor: Industrial

Title:  An Open-Label, Multicenter, Phase 1b Study of JNJ-54767414 (HuMaxCD38) (Anti-CD38 Monoclonal Antibody) in Combination with Backbone Regimens for the Treatment of Subjects with Multiple Myeloma

COH Protocol Number: 14179 ClinicalTrials.gov Number: NCT01526928

Principal Investigator: Karen Reckamp, MD
Sponsor: Industrial

Title:  A Phase 1/2, Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of Oral CO-1686 in Patients with Previously Treated Mutant EGFR Non-Small Cell Lung Cancer (NSCLC)

COH Protocol Number: 14171 ClinicalTrials.gov Number: NCT02216890

Principal Investigator: Sumanta Pal, MD
Sponsor: Industrial

Title:  A Phase 1 Trial of SGN-CD70A in Patients with CD70-positive Malignancies

COH Protocol Number: 14167 ClinicalTrials.gov Number: NCT02206763

Principal Investigator: Karen Reckamp, MD
Sponsor: Industrial

Title:  A Phase 1b Study of Erlotinib and Momelotinib for the Treatment of Epidermal Growth Factor Receptor (EGFR) Mutated EGFR Tyrosine Kinase Inhibitor (TKI) Naïve Metastatic Non-Small Cell Lung Cancer (NSCLC)

COH Protocol Number: 14166 ClinicalTrials.gov Number: NCT01786135

Principal Investigator: Robert Chen, MD
Sponsor: Industrial

Title:  A Phase 1, Open-Label, Dose-Escalation Study of SGN-CD19A in Patients with Relapsed or Refractory B-lineage Non-Hodgkins Lymphoma

COH Protocol Number: 14161 ClinicalTrials.gov Number: NCT02250157

Principal Investigator: Marwan Fakih, MD
Sponsor: Industrial

Title:  A Dose-regimen Finding Study to Evaluate Safety, Tolerability, Pharmacokinetics and Activity of Oratecan in Subjects with Advanced Malignancies

COH Protocol Number: 14160 ClinicalTrials.gov Number: NCT01962792

Principal Investigator: Chatchada Karanes, MD
Sponsor: Industrial

Title:  A Multicenter Phase 1/2b Study of the Bruton’s Tyrosine Kinase Inhibitor, Ibrutinib (PCI-32765), in Combination with Carfilzomib (Kyprolis™) in Subjects with Relapsed or Relapsed and Refractory Multiple Myeloma

COH Protocol Number: 14158 ClinicalTrials.gov Number: NCT02319369

Principal Investigator: Joseph Rosenthal, MD
Sponsor: Industrial

Title:  A Phase 1 Dose Escalation Study of DS-3032B, an Oral MDM2 Inhibitor, in Subjects with Acute Myelogenous Leukemia (AML), Acute Lymphocytic Leukemia (ALL), Chronic Myleogenous Leukemia (CML) in Blast Phase, or High-Risk Myelodysplastic Syndrome (MDS)

COH Protocol Number: 14157 ClinicalTrials.gov Number: NCT02354417

Principal Investigator: Anna Pawlowska, MD
Sponsor: Industrial

Title:  A Phase I Trial of a Single ProHema CB Product (EX Vivo Modulated Human Cord Blood Cells) Following Myeloablative Conditioning for Pediatric Patients with Hematologic Malignancies

 
Results per page: 25 50 100 All 1-25 Trials Jump to page:

 
 
  
NCI CCC LogoCity of Hope, An NCI-designated Comprehensive Cancer Center, is an innovative biomedical research, treatment and educational institution dedicated to the prevention and cure of cancer and other life-threatening illness.
Best Of logoCity of Hope has been named one of "America's Best Hospitals" in cancer and gynecology by U.S. News & World Report. Read more here...
NCI CCC LogoThe National Comprehensive Cancer Network (NCCN), a not-for-profit alliance of 21 of the world’s leading cancer centers, is dedicated to improving the quality and effectiveness of care provided to patients with cancer.
Best Of logoWe subscribe to the HONcode of the Healthcare on the Net Foundation.